

CORE

Title	A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori
Author(s)	Chu, KM; Kwok, KF; Choi, HK; Law, SYK; Branicki, FJ; Wong, J
Citation	Challenges to specialists in the 21st century, the 1st International Congress of Hong Kong Academy of Medicine, Hong Kong Medical Journal, Hong Kong, China, 26-29 November 1998, v. 4 n. 4 Supp, p. 16
Issued Date	1998
URL	http://hdl.handle.net/10722/47000
Rights	Creative Commons: Attribution 3.0 Hong Kong License

<b>6.5</b> A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of <i>Helicobacter pylori</i>	KM Chu, <u>KF Kwok</u> , HK Choi, SYK Law, FJ Branicki, J Wong Department of Surgery, University of Hong Kong Medical Centre, Qucen Mary Hospital, Hong Kong, China	Ain: We prospectively compared omeprazole-based dual and triple therapics in the eradication of <i>H pylori</i> in a randomized mannet. Methods: Between June 1995 and March 1997, 1000 consecutive patients with acid-peptic disease associated with <i>H pylori</i> infection (duodenal ulcer 388 patients: gastric ulcer 179 patients: duodeniis 173 patients: gastriits 260 patients) were prospectively recruited. They were randomized to either a two weeks (OA) course of omeprazole 20 mg and amoxicillin lg both given twice daily, or recattenent for one week (OCM) with omeprazole 20 mg once daily, clarithromycin 500 mg uvice daily, and metronidaxole 400 mg twice daily, or reatment for one week (OCM) with omeprazole 20 mg once daily, or 54.9 years. Side effects occurred in 29.6% (95% CI 8.0% - 13.6%) and 10.6% (95% CI 8.0% - 13.6%) of patients ranged from 16 to 90 years with a mean of 54.9 years. Side effects occurred in 29.6% (95% CI 8.0% - 13.6%) and 10.6% (95% CI 8.0% - 13.6%) of patients ranged from 16 to 90 years with a mean of 54.9 years. Side effects between the two groups. One patient of the OA group and four patients ranged from 16 to 90 years with a mean of 54.9 years. Side effects herewere, there were no significant differences in the incidences of side effects between the two groups. One patient of the OA group and four patients of the OA groups. One patient of the OA group and four patients of the OA group score); <i>Findings</i> were significant di threen patients of the OA group and four patients of the OA group score); <i>Findings</i> and thirteen patients of the OA group and four patients of the OA group 23.5% (95% CI 34% - 77.4%) and 97.5% (95% CI 39.5% - 91.2%). Respectively (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.10.9%) (75.0%) (75.10.9%) (75.10.9%) (75.10.9%) (75.0%) (75.
6.4 D3 gastrectomy for potentially curable stomach cancer: a long-term follow-up study	<u>EKW Ng.</u> N Hayes, SA Raimes, TJ Crofts, SDS Woods, MS Griffin, SCS Chung Department of Surgery, Prince of Wales Hospital, Hong Kong, China	<b>Background:</b> Gastrectomy with extended lymphadenectomy is the advocated treatment in Japan for patients with "curable" stomach cancer. Attempts of the technique in units elsewhere failed to show any survival advantage. This study aims to examine the safety and efficacy of radical gastrectomy with a Far East centre outside Japan. <b>Methods:</b> A consecutive series of 121 patients with gastric cancer who fuffiled criteria for radical surgery had total gastrectomy with extended lymphadenectomy equivalent to D3 dissection over a six-year period in a single unit. Early postoperative events were documented prospectively, and all patients were followed up on a 3 monthly basis thereafter. Investigation and/or intervention were performed whenever there was clinical suspicion of tumour recurrence. <b>Results:</b> The operation carried a morbidity of 50 percent, with a performed whenever there was clinical suspicion of tumour recurrence. <b>Concommented by tumor stage:</b> five-year survival for patients with intact gastric serosa was 64 percent, <i>versus</i> 10 percent of those with serosal penetration (Chi square=39.4, P < 0.00001). The majority of documented by tumor stage: five-year survival for patients with intact gastric serosa was 64 percent, <i>versus</i> 10 percent of those with serosal penetration (Chi square=39.4, P < 0.00001). The majority of documented metastases occurred by trans-peritoneal route for serosa-negative. <b>Conclusions:</b> Radical gastrectomy with extended by tumor stage: five-year survival for patients, but via the hematogenous mechanisms for thereabenet to were serosa-negative morbidity. Absence of survival benefit is mainly resulted from loco-regional recurrence in patients with 13/T4 diseases. Novel approaches including neo-adjuvant treatment for downstaging of disease and adjuvant regional therapy for stringent local control should be explored.